06160

230.8004.86%
MH

Margaret Han Dugan

Member of Scientific Advisory Committee & Independent Non-Exec. Director

Dr. Margaret Han Dugan, M.D. has been the Chief Medical Officer at Whitehawk Therapeutics, Inc. since December 2025. She joined Schr?dinger, Inc. in 2023 and served as its Chief Medical Officer since July 2023 until 2025. She serves as Member of Scientific Advisory Board and Commercial & Medical Affairs Advisory Committee of BeOne Medicines Ltd. (formerly known as BeiGene, Ltd.) and is its Independent Non-Executive Director from June 11, 2026. She is Member of Scientific Advisory Board at SonALAsense, Inc. She has led several drug development programs in oncology through FDA approval, including temozolomide, the standard of care in GBM. She is Independent Non-Executive Director of BeOne Medicines Ltd. (formerly known as BeiGene, Ltd.) from February 01, 2022. Dr. Dugan is currently Chief Medical Officer at Dracen Pharmaceuticals. She joined Dracen in 2018 with experience in oncology and previously held senior leadership roles at Novartis Oncology, including Senior Vice President and Global Program Head, developing innovative medicines for patients. Dr. Dugan also held several development positions at Schering-Plough (now Merck & Co.) and American Cyanamid (now Pfizer). Dr. Dugan received her B.A. and medical degrees and training in hematology and oncology from New York University.

Positions